Related Experiment Videos
Growth fraction measured using the comet assay.
1British Columbia Cancer Research Centre, Vancouver, Canada.
Cell Proliferation
|September 1, 1992
Summary
A new comet assay accurately measures cancer cell proliferation (growth fraction) by detecting DNA strand breaks caused by etoposide. This method shows promise for predicting tumor response to cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tumor growth fraction is a critical factor influencing cancer treatment efficacy.
- Accurate measurement of growth fraction is essential for predicting therapeutic response.
- Existing methods for assessing proliferation may lack speed or accuracy.
Purpose of the Study:
- To introduce and validate a novel assay for measuring cancer cell growth fraction.
- To assess the utility of the alkaline comet assay for quantifying proliferating cells.
- To determine if this assay can predict tumor response to therapy.
Main Methods:
- Utilized the alkaline comet assay to detect DNA strand breaks induced by etoposide in WiDr colon carcinoma cells.
- Defined growth fraction as the proportion of cells exhibiting elevated DNA strand breaks.
- Validated assay specificity using bromodeoxyuridine (BrdUrd) incorporation and anti-BrdUrd antibodies, and correlated results with Ki-67 staining.
Main Results:
- The comet assay successfully identified proliferating cells by detecting etoposide-induced DNA strand breaks.
- Assay specificity was confirmed as all bromodeoxyuridine-labeled cells showed DNA damage.
- Growth fraction measurements using the comet assay showed strong correlation with Ki-67.
Conclusions:
- The alkaline comet assay provides an accurate, rapid, and convenient method for measuring cancer cell growth fraction.
- This novel assay has potential applications in predicting human cancer response to various therapies.
- Further studies are warranted to establish its clinical utility in diverse cancer types.